Form 4: Kura Oncology SVP Granted Equity Awards

Kura Oncology's SVP of Finance & Accounting, Thomas James Doyle, received grants of Restricted Stock Units and stock options, increasing his beneficial ownership.

Summary

• Thomas James Doyle, SVP, Finance & Accounting at Kura Oncology, Inc., was granted 21,250 Restricted Stock Units (RSUs) and 42,500 stock options on January 2, 2026.
• The RSUs were granted at a price of $0 and will vest in four equal annual installments starting January 26, 2027, through January 26, 2030.
• The stock options have an exercise price of $10.335 and will vest in 48 equal monthly installments commencing on the grant date, expiring on January 1, 2036.
• Following these transactions, Mr. Doyle directly beneficially owns 152,309 shares of common stock and 42,500 options.
• He also indirectly beneficially owns 500 shares through his spouse's 401(k).
• The transactions were made pursuant to a Rule 10b5-1(c) plan.
• The reported beneficial ownership includes 802 shares acquired on November 17, 2025, via the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation grants to a senior executive, which is a standard practice for executive retention and incentive. It does not contain information that would significantly alter the company's fundamental outlook, but it does signal continued alignment of management's interests with long-term shareholder value.

Positives

• Grant of 21,250 Restricted Stock Units (RSUs) at $0, aligning management's interests with shareholders.
• Grant of 42,500 stock options with an exercise price of $10.335, providing an incentive for future stock price appreciation.
• The transactions were made under a Rule 10b5-1(c) plan, indicating pre-planned equity compensation.

Future Outlook

The vesting schedules for the RSUs and stock options extend into 2030 and 2036 respectively, indicating a long-term incentive structure for the SVP of Finance & Accounting.

Industry Context

Equity grants to senior executives like the SVP of Finance & Accounting are a standard practice in the biotechnology and pharmaceutical industry, including oncology, to attract, retain, and incentivize key talent. These grants align executive interests with long-term shareholder value creation, particularly important in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• Equity compensation packages, including a mix of Restricted Stock Units (RSUs) and stock options, are common across the biotechnology and pharmaceutical industry for senior executives.
• The vesting schedules (four-year annual for RSUs, four-year monthly for options) are typical for long-term incentive plans designed to retain executives and encourage sustained performance, comparable to practices at companies like Amgen, Gilead Sciences, or Regeneron Pharmaceuticals.
• The grant of RSUs at a $0 price is standard for such awards, representing a direct share grant subject to vesting conditions.
• The option exercise price of $10.335 would typically be the closing market price on the grant date, a standard practice to ensure compliance and fair valuation.

Related Party Transactions

• Indirect beneficial ownership of 500 shares through the spouse's 401(k) is disclosed, which is a standard reporting requirement for beneficial ownership.

Stakeholder Impact

• Shareholders: The grants align the interests of a key executive with long-term shareholder value creation, potentially fostering sustained performance.
• Employees: Standard executive compensation practices can influence overall compensation philosophy and morale.
• Management: Provides long-term incentives and retention for the SVP of Finance & Accounting.

Next Steps

• The RSUs will vest in four equal annual installments on January 26, 2027, January 26, 2028, January 26, 2029, and January 26, 2030.
• The stock options will vest in 48 equal monthly installments commencing on the grant date of January 2, 2026.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a senior executive and does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily reflects standard executive incentive practices.

Keywords

Kura Oncology, KURA, Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Executive Compensation, Thomas James Doyle, SVP Finance & Accounting, Rule 10b5-1